English

Eligibility Criteria

6 forms  
  1. StudyEvent: SEV1
    1. Eligibility Criteria
    2. Subject ID, consent group, subject source, subject source ID, and affection status of participants with acute myeloblastic leukemia and involved in the "Analysis of Somatic Mutations in Pediatric AML FAB-M7 Subtype by Whole Transcriptome Sequencing" project.
    3. Sample ID, subject ID, sample source, sample source ID, and sample use variables obtained from participants with acute myeloblastic leukemia and involved in the "Analysis of Somatic Mutations in Pediatric AML FAB-M7 Subtype by Whole Transcriptome Sequencing" project.
    4. Sample ID, body site where sample was collected, analyte type of samples, tumor status, histological type of samples, and primary tumor location obtained from participants with acute myeloblastic leukemia and involved in the "Analysis of Somatic Mutations in Pediatric AML FAB-M7 Subtype by Whole Transcriptome Sequencing" project.
    5. Subject ID, age at diagnosis, ethnicity, gender, relapse and vital status, if patient receive a bone marrow transplant, primary treatment protocol, disease code, genetic lesions, characteristic of specimen including tumor purity, type of specimen, and tissue site where from the specimen was obtained from participants with acute myeloblastic leukemia and involved in the "Analysis of Somatic Mutations in Pediatric AML FAB-M7 Subtype by Whole Transcriptome Sequencing" project.
    6. Sample ID and GEO accession ID of participants with acute myeloblastic leukemia and involved in the "Analysis of Somatic Mutations in Pediatric AML FAB-M7 Subtype by Whole Transcriptome Sequencing" project.
Inclusion and exclusion criteria
Description

Inclusion and exclusion criteria

Cases of acute megakaryoblastic leukemia as determined by morphology and flow cytometry of diagnostic bone marrow and/or peripheral blood samples. The cases in this cohort have had transcriptome sequencing of RNA (N=14) as well as whole genome sequencing (N=4) and exome sequencing (N=15) of tumor and normal DNA performed. Cases were selected that had appropriate consent for genetic studies, and suitable material for sequencing (high purity tumor populations and available normal DNA obtained at disease remission).
Description

Elig.phs000413.v2.p1.1

Data type

boolean

Alias
UMLS CUI [1,1]
C0023462
Back to the top of the page

Similar models

Eligibility Criteria

6 forms
  1. StudyEvent: SEV1
    1. Eligibility Criteria
    2. Subject ID, consent group, subject source, subject source ID, and affection status of participants with acute myeloblastic leukemia and involved in the "Analysis of Somatic Mutations in Pediatric AML FAB-M7 Subtype by Whole Transcriptome Sequencing" project.
    3. Sample ID, subject ID, sample source, sample source ID, and sample use variables obtained from participants with acute myeloblastic leukemia and involved in the "Analysis of Somatic Mutations in Pediatric AML FAB-M7 Subtype by Whole Transcriptome Sequencing" project.
    4. Sample ID, body site where sample was collected, analyte type of samples, tumor status, histological type of samples, and primary tumor location obtained from participants with acute myeloblastic leukemia and involved in the "Analysis of Somatic Mutations in Pediatric AML FAB-M7 Subtype by Whole Transcriptome Sequencing" project.
    5. Subject ID, age at diagnosis, ethnicity, gender, relapse and vital status, if patient receive a bone marrow transplant, primary treatment protocol, disease code, genetic lesions, characteristic of specimen including tumor purity, type of specimen, and tissue site where from the specimen was obtained from participants with acute myeloblastic leukemia and involved in the "Analysis of Somatic Mutations in Pediatric AML FAB-M7 Subtype by Whole Transcriptome Sequencing" project.
    6. Sample ID and GEO accession ID of participants with acute myeloblastic leukemia and involved in the "Analysis of Somatic Mutations in Pediatric AML FAB-M7 Subtype by Whole Transcriptome Sequencing" project.
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Inclusion and exclusion criteria
Elig.phs000413.v2.p1.1
Item
Cases of acute megakaryoblastic leukemia as determined by morphology and flow cytometry of diagnostic bone marrow and/or peripheral blood samples. The cases in this cohort have had transcriptome sequencing of RNA (N=14) as well as whole genome sequencing (N=4) and exome sequencing (N=15) of tumor and normal DNA performed. Cases were selected that had appropriate consent for genetic studies, and suitable material for sequencing (high purity tumor populations and available normal DNA obtained at disease remission).
boolean
C0023462 (UMLS CUI [1,1])
Back to the top of the page